|NantKwest Announces Enhanced High-Affinity Activated Natural Killer (haNK) Cell Therapy in Preclinical Studies of HER2 Positive Breast Cancer at Presentation at the San Antonio Breast Cancer Symposium|
Previous studies have shown that patients with HER2 positive breast cancer who have the high-affinity CD16 receptor that have been treated with Herceptin (trastuzumab) had better clinical outcomes versus those without the high affinity receptor. In this study, in a mouse xenograft model of HER2 positive breast cancer, to enhance the activity of aNK (activated natural killer) cell therapy aNK cells were engineered to express the CD16 high affinity Fc receptor (haNK cells). Study results reported provide further supporting evidence that antibody-dependent cellular cytotoxicity (ADCC) mediated cancer cell killing can be further enhanced through the recognition of the Fc fragment of a therapeutic antibody, in this case Herceptin, and the haNK cell’s CD16 Fc receptor.
“In over 50 patients in a broad range of cancer types, NantKwest’s aNK
cell therapy has demonstrated promising indications of efficacy and an
excellent safety record,” said
Collaborating on the study were research scientists from
NantBiosciences, NantCell and
This poster reviews the potential synergistic use of haNK cell therapy in combination with Herceptin (trastuzumab) in patients with HER2-positive breast cancer.
NantKwest’s unique NK cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: (1) Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact, (2) Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and (3) Targeted activated killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of T cell
therapies including the reduction of risk of serious "cytokine storms"
reported after T cell therapy. As an “off-the-shelf” therapy,
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs that include a Phase 2 trial
for a rare form of melanoma and the planned initiation of a clinical
trial of NK cells targeted to breast cancer, we believe